Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Indivior Pharmaceuticals Inc. (INDV : NSDQ)

• Company Description    Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. Number of Employees: 1,051

• Price / Volume Information    Yesterday's Closing Price: $34.58 Daily Weekly Monthly 20 Day Moving Average: 1,429,316 shares Shares Outstanding: 125.02 (millions) Market Capitalization: $4,323.19 (millions) Beta: 0.80 52 Week High: $38.00 52 Week Low: $7.62 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 6.27% 7.88% 12 Week 5.59% 1.99% Year To Date -3.62% -3.49%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10710 Midlothian Turnpike Suite 125 - North Chesterfield,VA 23235 USA ph: 804-379-1040 fax: 804-379-1215 investorrelations@indivior.com http://www.indivior.com

• General Corporate Information    Officers Mark Crossley - Chief Executive Officer David Wheadon - Chairman Ryan Preblick - Chief Financial Officer Woodrow Anderson - Senior Vice President Juliet Thompson - Director Peer Information Indivior Pharmaceuticals Inc. (GSAC) Indivior Pharmaceuticals Inc. (CASI) Indivior Pharmaceuticals Inc. (ALCD.) Indivior Pharmaceuticals Inc. (OMNN) Indivior Pharmaceuticals Inc. (CGPI.) Indivior Pharmaceuticals Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 45579U109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 125.02 Most Recent Split Date: (:1) Beta: 0.80 Market Capitalization: $4,323.19 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.64 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $2.89 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: 11.95 Trailing 12 Months: 17.64 PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: 19.00 Price / Sales: 3.66 EPS Growth vs. Year Ago Period: 33.33% vs. Previous Quarter: 41.18% Sales Growth vs. Year Ago Period: 2.28% vs. Previous Quarter: 3.97% ROE 12/31/25 - - 09/30/25 - -90.79 06/30/25 - -86.28 ROA 12/31/25 - - 09/30/25 - 17.91 06/30/25 - 16.26 Current Ratio 12/31/25 - - 09/30/25 - 0.96 06/30/25 - 0.90 Quick Ratio 12/31/25 - - 09/30/25 - 0.79 06/30/25 - 0.76 Operating Margin 12/31/25 - - 09/30/25 - 21.10 06/30/25 - 19.44 Net Margin 12/31/25 - - 09/30/25 - 9.83 06/30/25 - 6.65 Pre-Tax Margin 12/31/25 - - 09/30/25 - 16.10 06/30/25 - 15.60 Book Value 12/31/25 - - 09/30/25 - - 06/30/25 - - Inventory Turnover 12/31/25 - - 09/30/25 - 1.41 06/30/25 - 1.26 Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - -

Powered by Zacks Investment Research ©